register

News & Trends - Pharmaceuticals

TGA approves Vertex’s cystic fibrosis therapy 6-11 year olds

Health Industry Hub | November 3, 2022 |

Pharma News: Vertex announced that the Australian Therapeutic Goods Administration (TGA) has approved the use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for children with cystic fibrosis (CF) ages 6-11 years who have at least one F508del mutation in the CF transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation worldwide.

Cystic Fibrosis begins at birth and leads to cumulative health decline over time, and premature death. In paediatric patients, there is evidence of early structural lung damage, even prior to the emergence of symptoms, including those of a respiratory nature.
“This approval follows the recent PBS listing for those ages 12 years and older and demonstrates our continued commitment to broaden access to younger Australians with CF,” said Sabrina Barbic, Senior Country Manager, Australia and New Zealand, Vertex Pharmaceuticals.

“We now look forward to the outcome of the Pharmaceutical Benefits Advisory Committee (PBAC) meeting in November, at which Trikafta will be considered for reimbursement for this younger age group. We will continue to work tirelessly alongside the CF community and other stakeholders in an effort to bring Trikafta to all Australian patients who can benefit.”

Trikafta was approved by the TGA based on the results of data from a 24-week Phase 3 study, which evaluated the safety and efficacy of Trikafta in children ages 6-11 years with at least one F508del mutation.


News & Trends - MedTech & Diagnostics

Federal Health Minister meets with private hospital leaders to tackle sector reforms

Federal Health Minister meets with private hospital leaders to tackle sector reforms

Health Industry Hub | June 20, 2024 |

MedTech & Diagnostics News: In the past five years, 71 private hospital services have closed down as a result of […]

More


News & Trends - Pharmaceuticals

Medicines Australia warns against panic buying or stockpiling of drugs facing supply shortages

Medicines Australia warns against panic buying or stockpiling of drugs facing supply shortages

Health Industry Hub | June 20, 2024 |

Pharma News: Over 400 medicines are currently facing shortages nationwide, according to the Therapeutic Goods Administration (TGA). Among these, 39 […]

More


News & Trends - MedTech & Diagnostics

HCF partners with clinicians to optimise colonoscopy procedures in public hospitals

HCF partners with clinicians to optimise colonoscopy procedures in public hospitals

Health Industry Hub | June 20, 2024 |

MedTech & Diagnostics News: As Australia marks Bowel Cancer Awareness Month this June, the HCF Research Foundation highlights its support […]

More


Digital & Innovation

Australian AI-powered tool promises rapid stroke detection

Australian AI-powered tool promises rapid stroke detection

Health Industry Hub | June 20, 2024 |

Digital & Innovation: An Australian innovation promises to transform stroke care by enabling quicker intervention and improving patient outcomes through […]

More


This content is copyright protected. Please subscribe to gain access.